journal article·2025-06-10

Targeted Knockdown of Epithelial Estrogen Receptor α to Mitigate Ferroptosis and Epithelial–Mesenchymal Transition in Eosinophilic Asthma

Weiyun Zhang, Shengding Zhang, Lijuan Hua, Wenxue Bai, Lu Qin, Junqing Yue, Dongyuan Wang, Mengyao Guo, Xuezhao Wang, Harald Renz, Skevaki Chrysanthi, Gang Wang, Zhihong Chen, Haifeng Dong, Min Xie

ACS Nano· Volume 19· Issue 22
Publisher page

Abstract

Estrogen receptor α (ERα) is involved with the hyperresponsiveness and airway remodeling in asthma, but developing therapies targeting ERα remains challenging due to its multifaceted roles in different cell types and the poor efficacy of systemic ERα intervention in asthma. Previously, we uncovered the association of increased ERα expression in airway epithelial cells with poor pulmonary function and epithelial-mesenchymal transition (EMT) in asthma patients. This study further investigated the association of ERα expression with the ferroptosis and EMT levels in a cohort of eosinophilic asthma (EA) patients as well as in an eosinophil-epithelial coculture cell model. By loading small interfering RNA (siRNA) into a mesoporous silica nanoparticle (MSN) and then coating the extracted bronchial epithelial cytomembrane (CM), a bronchial epithelial CM home-targeting nanoplatform (siRNA@MSN@CM) was constructed to selectively decrease the ERα expression in bronchial epithelial cells. The targeting effect of bronchial epithelial cells was confirmed in vitro and in vivo, demonstrating the successful targeted knockdown of ERα expression. Silencing ERα in epithelial cells effectively prevented ferroptosis and EMT induced by coculturing with ferroptotic eosinophils. Targeted intervention of epithelium ERα with intratracheal delivery of siRNA(ERα)@MSN@CM nanoparticle significantly reduced the levels of ferroptosis in bronchial epithelial cells, airway inflammation, and airway remodeling in asthmatic mouse models. This study introduces an innovative nanomaterial for targeted drug delivery to epithelial cells and underscores the potential of targeted knockdown ERα in bronchial epithelial cells as a therapeutic strategy for asthma treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Asthma and respiratory diseases · Eosinophilic Esophagitis · IL-33, ST2, and ILC Pathways

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College

Huazhong University of Science and Technology

Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, School of Biomedical Engineering

Shenzhen University Medical School

Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College

Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1519 Dongyue Avenue, Nanchang 330006, P. R. China

Department of Pulmonary and Critical Care Medicine

National Regional Center for Respiratory Medicine, Jiangxi Hospital of China-Japan Friendship Hospital

Key Laboratory of Respiratory Diseases

National Ministry of Health of the People’s Republic of China and National Clinical Research Center for Respiratory Disease

Institute of Laboratory Medicine

Philipps University Marburg

Universities of Giessen and Marburg Lung Center (UGMLC)

German Center for Lung Research (DZL)

Department of Respiratory and Critical Care Medicine, Clinical Research Center for Respiratory Disease

West China Hospital, Sichuan University

Department of Respiratory and Critical Care Medicine, Zhongshan Hospital

Fudan University

Funding

National Natural Science Foundation of China

References (29)

Show source-provided references
1. 10.1136/bmj.m23410.1136/bmj.m234 ↗
2. 10.1016/S0140-6736(19)31147-X10.1016/S0140-6736(19)31147-X ↗
3. 10.1186/s12931-020-1291-810.1186/s12931-020-1291-8 ↗
4. 10.1016/j.jaci.2015.05.04610.1016/j.jaci.2015.05.046 ↗
5. 10.4168/aair.2023.15.5.61410.4168/aair.2023.15.5.614 ↗
6. 10.1016/j.jaci.2021.12.76910.1016/j.jaci.2021.12.769 ↗
7. 10.1186/s13293-022-00483-710.1186/s13293-022-00483-7 ↗
8. 10.1126/science.121965710.1126/science.1219657 ↗
9. 10.1002/adma.20110476310.1002/adma.201104763 ↗
10. 10.1016/j.biopha.2018.10.16710.1016/j.biopha.2018.10.167 ↗
11. 10.1016/j.biomaterials.2012.10.07210.1016/j.biomaterials.2012.10.072 ↗
12. 10.7150/thno.826310.7150/thno.8263 ↗
13. 10.1016/j.apsb.2017.11.00910.1016/j.apsb.2017.11.009 ↗
14. 10.1002/adma.20180788810.1002/adma.201807888 ↗
15. 10.1002/INMD.2024001410.1002/INMD.20240014 ↗
16. 10.1021/acsnano.6b0469510.1021/acsnano.6b04695 ↗
17. 10.1002/adma.20150608610.1002/adma.201506086 ↗
18. 10.1038/s41571-020-00462-010.1038/s41571-020-00462-0 ↗
19. 10.1080/15548627.2020.181091810.1080/15548627.2020.1810918 ↗
20. 10.1016/j.jsbmb.2016.03.03210.1016/j.jsbmb.2016.03.032 ↗
21. 10.1161/HYPERTENSIONAHA.116.0766810.1161/HYPERTENSIONAHA.116.07668 ↗
22. 10.1016/j.redox.2020.10153010.1016/j.redox.2020.101530 ↗
23. 10.1177/101042831772618410.1177/1010428317726184 ↗
24. 10.1186/1471-2466-13-1110.1186/1471-2466-13-11 ↗
25. 10.1136/thoraxjnl-2020-21476410.1136/thoraxjnl-2020-214764 ↗
26. 10.1590/1516-3180.2016.01182701610.1590/1516-3180.2016.011827016 ↗
27. 10.1186/s40413-017-0177-910.1186/s40413-017-0177-9 ↗
28. 10.1002/smll.20180410510.1002/smll.201804105 ↗
29. 10.1186/s12931-021-01808-710.1186/s12931-021-01808-7 ↗